Biote Corp. reported a total revenue of $192.2 million for the fiscal year ending December 31, 2025, a decrease of 2.5% from $197.2 million in 2024. The decline was primarily driven by a $13.3 million drop in procedure revenue, attributed to a slowdown in new clinic additions and a decrease in procedure volume from existing Biote-certified practitioners. However, this was partially offset by a $6.9 million increase in revenue from Biote-branded dietary supplements, which benefited from enhanced e-commerce efforts, particularly through Amazon. The company also noted a $1.1 million increase in revenue from the sale of disposable trocars and bioidentical hormone pellets.
Net income for Biote Corp. was $31.6 million in 2025, a significant increase from $0.05 million in the previous year. This improvement was aided by a reduction in selling, general, and administrative expenses, which fell to $101.8 million from $107.5 million in 2024. The decrease was largely due to the absence of legal settlement expenses that had impacted the previous year’s results. Additionally, the company reported a gain from the change in fair value of earnout liabilities, amounting to $13 million, compared to a loss of $19.6 million in 2024.
Strategically, Biote has focused on expanding its practitioner network, with over 9,200 certified practitioners across more than 5,300 clinics as of December 31, 2025. The company aims to increase the adoption of its Biote Method, which provides hormone optimization solutions, and has implemented a comprehensive training and support platform for its practitioners. The company also completed several acquisitions, including Asteria Health, a 503B outsourcing facility for compounding bioidentical hormones, which is expected to enhance its operational capabilities.
Operationally, Biote reported approximately 400,000 active patients and a retention rate of over 91% among its practitioners. The company has also seen a significant increase in its employee headcount, reaching 223 as of December 31, 2025. Despite these positive indicators, Biote faces challenges, including regulatory scrutiny and competition in the hormone optimization market. The company’s outlook remains cautiously optimistic, with plans to continue expanding its geographic footprint and product offerings while navigating the complexities of the regulatory landscape.
Looking ahead, Biote Corp. anticipates continued growth in the hormone optimization market, which is projected to exceed $7 billion by 2026. The company is committed to enhancing its product offerings and expanding its practitioner network, although it acknowledges potential risks related to market acceptance, regulatory changes, and competition. The management's focus on long-term growth may impact short-term profitability, but they believe this strategy will ultimately enhance shareholder value.
About biote Corp.
Biote Corp. provides a practice-building platform for healthcare practitioners specializing in hormone optimization, primarily through education, certification, practice management software, and proprietary clinical tools. It offers bioidentical hormone therapies, including pellets and topical formulations, along with a line of dietary supplements targeting aging populations. Serving a large, growing market, the company emphasizes practitioner training, brand recognition, and a scalable, fee-based revenue model.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.